Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen R Fischer

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Validation of molecular and immunological factors with predictive importance in lung cancerJürgen R Fischer, Harald Lahm
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Future developments in the treatment of lung cancerFred R Hirsch, Jürgen R Fischer, Jacek Niklinski, et al.
The Annals of Thoracic Surgery|December 3, 2014
Unexpected lymph node disease in resections for pulmonary metastasesGernot Seebacher, Steffen Decker, Jürgen R Fischer, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2007
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabineJürgen R Fischer, Ute Ohnmacht, Norman Rieger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancerWolf Köster, Andrea Heider, Norbert Niederle, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2006
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesotheliomaJürgen R Fischer, Ute Ohnmacht, Norman Rieger, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Clinical Lung Cancer|June 7, 2016
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyDavid Planchard, Takashi Yokoi, Michael J McCleod, et al.
The Oncologist|September 19, 2014
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinibMartin Schuler, Jürgen R Fischer, Christian Grohé, et al.
Respiration; International Review of Thoracic Diseases|November 7, 2013
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancerMichael Kreuter, Johan Vansteenkiste, Felix J F Herth, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Validation of molecular and immunological factors with predictive importance in lung cancerJürgen R Fischer, Harald Lahm
Lung Cancer (Amsterdam, Netherlands)|December 7, 2002
Future developments in the treatment of lung cancerFred R Hirsch, Jürgen R Fischer, Jacek Niklinski, et al.
The Annals of Thoracic Surgery|December 3, 2014
Unexpected lymph node disease in resections for pulmonary metastasesGernot Seebacher, Steffen Decker, Jürgen R Fischer, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2007
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabineJürgen R Fischer, Ute Ohnmacht, Norman Rieger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancerWolf Köster, Andrea Heider, Norbert Niederle, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2006
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesotheliomaJürgen R Fischer, Ute Ohnmacht, Norman Rieger, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Clinical Lung Cancer|June 7, 2016
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyDavid Planchard, Takashi Yokoi, Michael J McCleod, et al.
The Oncologist|September 19, 2014
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinibMartin Schuler, Jürgen R Fischer, Christian Grohé, et al.
Respiration; International Review of Thoracic Diseases|November 7, 2013
Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancerMichael Kreuter, Johan Vansteenkiste, Felix J F Herth, et al.
Pageof 4